The following is a summary of the OrthoPediatrics Corp. (KIDS) Q3 2024 Earnings Call Transcript:

Financial Performance:

• OrthoPediatrics reported a Q3 2024 revenue of $54.6 million, a 37% increase year-over-year.

• Gross profit margin for Q3 was 73%, a decrease from 77% in Q3 2023, attributed to product mix shifts and lower margin sales, notably the 7D units.

• Adjusted EBITDA for Q3 2024 was $4.0 million, up from $3.6 million in Q3 2023.

• Raised full year 2024 revenue guidance to $202 million to $204 million, indicating a 36% to 37% year-over-year growth.

Business Progress:

• OrthoPediatrics helped over 33,000 children in Q3, up 50% from last year. They have aided over 1 million children since inception.

• International performance was strong with revenue of $11.9 million, growing 12% year-over-year primarily due to trauma, deformity, and scoliosis products.

• Launched multiple sets of PNP Tibia and prepared to launch the P3 hip system in the first half of next year.

• Expanded OPSB with the acquisition of a small clinic in Florida and other greenfield expansions.

Opportunities:

• OrthoPediatrics saw expansions in trauma, deformity (T&D), scoliosis, and bracing businesses.

• Expect continued growth and expansion into international markets, notably with EU MDR approvals anticipated in mid-2025.

• Continuing to drive growth through aggressive market share gains, particularly in pediatric orthopedic products and the onboarding of new technologies like the 7D units and EOS products.

Risks:

• Exposure to market fluctuations due to viruses like flu and COVID which affect surgical scheduling.

• Variability in international markets potentially influenced by external factors such as local regulatory environments and distributor activities.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.